Colorectal Cancer, Metastatic Colorectal Cancer
Conditions
Brief summary
The goal of this exploratory phase I/II single-center clinical trial is to evaluate effectiveness, tolerability, and safety of Intravenous D-isoascorbic Acid (D-VC) With Arsenic Trioxide in Patients With Advanced/Metastatic Colorectal Cancer Who Have Exhausted Standard Therapy The main questions are to learn about effectiveness, tolerability, and safety of Intravenous D-isoascorbic Acid (D-VC) With Arsenic Trioxide. The study aims to: 1. Assess the tolerability and pharmacokinetics of D-isoascorbic acid (D-VC) with a single intravenous injection in the monotherapy regimen and in the sequential administration regimen with arsenic trioxide (ATO) in patients on standard therapy for advanced/metastatic malignancies (Phase I) 2. Evaluate the efficacy and safety of D-isoascorbic acid (D-VC) with repeated intravenous administration in the mode of sequential administration with arsenic trioxide (ATO) in patients who have exhausted standard therapy for advanced/metastatic colorectal cancer (Phase II) In phase I participants will receive single intravenous administration as monotherapy of D-isoascorbic acid (D-VC) with dose escalation (0.05, 0.1, 0.2 g/kg/day) and with arsenic trioxide (ATO). Patients who have satisfactorily tolerated the study drug in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial. To study the safety and efficacy of the study drug in phase II, D-VC after the administration of ATO will be implemented in 2 groups: Study group 1: ATO (at a dose of 0.15 mg / kg / day) after intravenous administration after 2 hours D-VC intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients. Group 2 standard therapy: 15 patients. For the phase I researchers will compare laboratory tests (including clinical biochemistry and hematology), vital signs, clinical adverse events (diseases, symptoms and complaints) and other specific safety tests (for example, an electrocardiogram, ophthalmic examination) between groups. They will also measure the degree to which overt adverse reactions can be subjectively tolerated by the subject of the study. For the phase II researchers will compare degrees of tumor volume reduction on CT; objective response rate (ORR) based on BICR according to RECIST v1.1 between test and standard therapy groups. They will also continue evaluation of safety and tolerability of ATO + D-VC combination therapy.
Interventions
COMBINATION_PRODUCTD-isoascorbic Acid (D-VC) With Arsenic Trioxide (ATO)
After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I. Phase 1 - Scheme 1 - single intravenous administration in monotherapy with dose escalation (0.05, 0.1, 0.15 g/kg/day); Scheme 2 - single intravenous administration in the mode of sequential administration with arsenic trioxide with dose escalation of D-isoascorbic acid (0.05, 0.1, 0.15 g/kg/day). Phase 2 - Study group 1: After 2 hours of intravenous administration of arsenic trioxide (ATO) (at a dose of 0.15 mg / kg / day) participants will further receive D-isoascorbic acid (D-VC) intravenously once a day at the maximum tolerated dose, determined at the end of phase I for at least 15 patients.
DRUGFOLFOX/FOLFIRI regimen
FOLFOX - oxaliplatin 85mg/m2 1 day Leucovorin 200mg/m2 IV 2h, 1, 2 days 5 - Fluorouracil 400mg/m2 IV bolus, 1, 2 days 5 - Fluorouracil 600mg/m2 IV 22h, 1, 2 days FOLFIRI Irinotecan 180 mg/m2 IV Leucovorin 400 mg/m2 IV Fluorouracil bolus 400 mg/m2 IV Fluorouracil infusional 2400 mg/m2 IV Courses are held every 2 weeks
Sponsors
National Laboratory Astana
Nazarbayev University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Phase 1: INCLUSION CRITERIA: * informed consent to participate in the study * patients of the second clinical group with malignant neoplasms of a common/metastatic form that have exhausted standard therapy. * patients who have received at least 3 lines of standard therapy, including those with the use of targeted drugs, patients who have exhausted the possibilities of using specialized drugs, as part of the recommendations of treatment protocols * the presence of + KRAS / NRAS status of the primary tumor or metastatic focus (determined in LEKzone 2, codons 12, 13, 61) * ≥1 measurable lesion defined by RECIST v1.1 * ECOG PS 0.1 or 2
Exclusion criteria
* age up to 18 years * pregnancy and lactation * patients with an autoimmune disease or with a medical diagnosis requiring systemic immunosuppression * decompensated diabetes mellitus * renal failure, urolithiasis * diabetes * thrombophlebitis, tendency to thrombosis * severe lung disease, dyspnea at rest, pleural effusion * cardiovascular insufficiency, ejection fraction of the heart \<40% * sensory neuropathy of the 1st degree of any etiology * uncontrolled infections * persons from the category of vulnerable patients (homeless, military personnel, incapacitated, patients in emergency conditions, other persons who may be subjected to pressure); * Allergy in history and during screening (drug, pollen, etc.); * participation in any other clinical trial; * hypersensitivity to arsenic; * individual intolerance to ascorbic acid; * thrombophlebitis and thrombosis, a tendency to thrombosis in history; * increased blood clotting and pathologies associated with this deviation; * diabetes; * nephrolithiasis or nephrolithiasis; * the patient does not agree to perform the procedures required by the protocol and is unable to adhere to the schedule of procedures. * if the patients have any other laboratory or other abnormalities, in the opinion of the Investigator, that can harm the patients and the results of the study. Phase II: INCLUSION CRITERIA: for both groups (30 patients, considering 20% decrease from the study): * informed consent to participate in the study * patients of the second clinical group with advanced/metastatic colorectal cancer * Patients must have previously received at least 3 lines of standard drug therapy, including those with the use of targeted drugs, who have exhausted the possibilities of using specialized drugs, as part of the recommendations of colorectal cancer treatment protocols - the presence of + KRAS / NRAS status of the primary tumor, or metastatic focus (determined in exon 2, codons 12, 13, 61) * ≥1 measurable lesion defined by RECIST v1.1 * ECOG PS 0.1 or 2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response to D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO) | Baseline, 4 weeks | Objective partial or complete response by RECIST 1.1, confirmed on a second CT scan at least 4 weeks apart |
| Change from baseline DV-C levels at 1 hour | Baseline, 1 hour | Patients who have satisfactorily tolerated D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial. |
| Change from baseline DV-C levels at 3 hours | Baseline, 3 hours | Patients who have satisfactorily tolerated D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial. |
| Change from baseline DV-C levels at 6 hours | Baseline, 6 hours | Patients who have satisfactorily tolerated D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial. |
| Change from baseline DV-C levels at 24 hours | Baseline, 24 hours | Patients who have satisfactorily tolerated D-isoascorbic Acid (D-VC) in combination with arsenic trioxide (ATO) in a phase I study are transferred to a phase II clinical trial. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 3 hours | Baseline, 3 hours | Adverse events in patients will be assessed by CTCAE v4.0 |
| Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 6 hours | Baseline, 6 hours | Adverse events in patients will be assessed by CTCAE v4.0 |
| Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 24 hours | Baseline, 24 hours | Adverse events in patients will be assessed by CTCAE v4.0 |
| Change from baseline number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 1 hour | Baseline, 1 hour | Adverse events in patients will be assessed by CTCAE v4.0 |
Countries
Kazakhstan
Contacts
Primary ContactDos Sarbassov, PhD
Outcome results
None listed